171 filings
Page 7 of 9
8-K
c5rzttx
3 Mar 17
Departure of Directors or Certain Officers
12:00am
8-K
ewuqqe lohozxc8
21 Feb 17
Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain
12:00am
8-K
41s5p
6 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
7s4oz0mwtxkat
4 Jan 17
Entry into a Material Definitive Agreement
12:00am
8-K
55e93rn5 8m
4 Jan 17
Regulation FD Disclosure
12:00am
8-K
lm9zxqxxjdlqjvf
19 Dec 16
Departure of Directors or Certain Officers
12:00am
8-K
8u6qrk7f
14 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
3jah8r
3 Nov 16
Trevena Reports Third Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
lslcia d26
4 Aug 16
Trevena Reports Second Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
jcstivak6h5sm5w1 aej
19 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
gtksjpcyf9
16 May 16
Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
12:00am
8-K
ydsl4
5 May 16
Trevena Reports First Quarter 2016 Financial Results
12:00am
8-K
tu1krtiqtgk0mo
2 May 16
Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
12:00am
8-K
ock21ivk5ceuq
9 Mar 16
Trevena Reports Full Year 2015 Financial Results
12:00am
8-K
v5xir0b83k 2xe
9 Mar 16
Departure of Directors or Certain Officers
12:00am
8-K
k7slz5gsepq
23 Feb 16
Other Events
12:00am
8-K
9mhl28k jlkjsra
23 Dec 15
Entry into a Material Definitive Agreement
12:00am
8-K
9jvef0ejqcg8ri xp4o1
14 Dec 15
Entry into a Material Definitive Agreement
12:00am
8-K
hsc4lrqb73335xp1y
11 Dec 15
Entry into a Material Definitive Agreement
12:00am
8-K
52ha 47lphg3atkq
10 Nov 15
Trevena Reports Third Quarter 2015 Financial Results
12:00am